In 2014, I became the Acting Director of the Women's Malignancies Branch. We are currently in the process of analyzing specimens and data from clinical trials 07C0058 - Bevacizumab and Sorafenib phase 2 in ovarian cancer; 08C0092 - Carboplatin and Olaparib in three cohort of patients: BRCA mutation carriers, high-grade serous ovarian cancer, triple negative breast cancer; and 09-C-0191 phase 1 study of bevacizumab and dasatinib. We have submitted for publication the results of clinical trial 12C0191 - SMAC-mimetic birinapant phase 2 in ovarian cancer. We currently have three clinical trials open to patient follow up (11C0022 - Pharmacokinetics of Carboplatin and Olaparib in women's cancers; 09C0019 - Bevacizumab and Dasatinib phase 1 trial; 12C0081 - Olaparib and Cederinib in ovarian cancer phase 1-2 trial). Two of our clinical trials are currently open to accrual: 14-C-0156 CHEK inhibitor for women with Triple Negative Breast Cancer and High Grade Serous Ovarian Cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Basic Sciences
Zip Code
Dull, Angie B; Wilsker, Deborah; Hollingshead, Melinda et al. (2018) Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis. Oncotarget 9:17104-17116
Annunziata, Christina M; Kohn, Elise C (2018) Clinical trials in gynecologic oncology: Past, present, and future. Gynecol Oncol 148:393-402
Del Carmen, Marcela G; Annunziata, Christina M; Rice, Laurel W (2017) The clinical trials crisis in gynecologic oncology. Gynecol Oncol 145:481-482
Wang, Ping-Yuan; Li, Jie; Walcott, Farzana L et al. (2017) Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. J Clin Invest 127:132-136
Zorn, Kristin K; Annunziata, Christina M (2016) Editorial: Inhibiting PARP as a Strategic Target in Cancer. Front Oncol 6:91
Noonan, Anne M; Bunch, Kristen P; Chen, Jin-Qiu et al. (2016) Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer 122:588-597